VINCRISTINE SULFATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C46H56N4O10.H2O4S
Molecular Weight	923.036
Optical Activity	UNSPECIFIED
Defined Stereocenters	9 / 9
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OS(O)(=O)=O.[H][C@@]12N3CC[C@@]14C5=CC(=C(OC)C=C5N(C=O)[C@@]4([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC)[C@]6(C[C@H]7CN(C[C@](O)(CC)C7)CCC8=C6NC9=CC=CC=C89)C(=O)OC

InChI

InChIKey=AQTQHPDCURKLKT-PNYVAJAMSA-N

InChI=1S/C46H56N4O10.H2O4S/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6;1-5(2,3)4/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3;(H2,1,2,3,4)/t28-,37-,38+,39+,42-,43+,44+,45-,46-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	H2O4S
Molecular Weight	98.078
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C46H56N4O10
Molecular Weight	824.9576
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	9 / 9
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.drugbank.ca/drugs/DB00541
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/vincristine.html

Vincristine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vincristine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vincristine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific. The antitumor activity of Vincristine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, Vincristine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca2+-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis.Vincristine was marketed under the brand name Oncovin, but was discontinued. In 2012 the FDA approved a Liposomal formulation of Vincristine, named MARQIBO KIT.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
transformed cell apoptotic process 106 Target ID: GO:0006927 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19137911	Activator 1404
Tubulin beta chain 8 Target ID: P07437 Gene ID: 203068.0 Gene Symbol: TUBB Target Organism: Homo sapiens (Human) Sources: http://www.drugbank.ca/drugs/DB00541	Inhibitor 8146
microtubule polymerization 19 Target ID: GO:0046785 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10920282	Inhibitor 8146	1.6 µM [IC50]
CCRF-CEM 4 Target ID: CHEMBL382 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22582991	Inhibitor 8146	0.17 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse 2 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202497s000lbl.pdf	Primary		Approved 8307	Marqibo Approved Use Marqibo® is indicated for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. Launch Date 1.34438401E12

C_max

Value	Dose	Co-administered	Analyte	Population
1220 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202497Orig1s000PharmR.pdf	2.25 mg/m² steady-state, intravenous dose: 2.25 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:		VINCRISTINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
14566 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202497Orig1s000PharmR.pdf	2.25 mg/m² steady-state, intravenous dose: 2.25 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:		VINCRISTINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
25% OTHER GOV https://www.medsafe.govt.nz/profs/Datasheet/v/Vincristinesulfatempinj.pdf			VINCRISTINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
2.25 mg/m2 1 times / week multiple, intravenous MTD Dose: 2.25 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2.25 mg/m2, 1 times / week Co-administed with:: dexamethasone, i.v.(40 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6	unhealthy, 19-62 n = 18 Health Status: unhealthy Condition: Acute lymphoblastic leukemia Age Group: 19-62 Sex: M+F Population Size: 18 Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6	Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6
2.4 mg/m2 1 times / week multiple, intravenous Studied dose Dose: 2.4 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2.4 mg/m2, 1 times / week Co-administed with:: dexamethasone, i.v.(40 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6	unhealthy, 19-62 n = 7 Health Status: unhealthy Condition: Acute lymphoblastic leukemia Age Group: 19-62 Sex: M+F Population Size: 7 Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6	DLT: Motor polyneuropathy, Seizure... Dose limiting toxicities: Motor polyneuropathy (grade 3, 14.3%) Seizure (grade 4, 14.3%) Hepatotoxicity (grade 4, 14.3%) Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6
2.8 mg/m2 3 times / week multiple, intravenous Highest studied dose Dose: 2.8 mg/m2, 3 times / week Route: intravenous Route: multiple Dose: 2.8 mg/m2, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701	unhealthy, 32-83 n = 3 Health Status: unhealthy Condition: Cancer Age Group: 32-83 Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701	DLT: Neutropenia, Thrombocytopenia... Dose limiting toxicities: Neutropenia (grade 4, 33.3%) Thrombocytopenia (grade 4, 33.3%) Obstipation Myalgia (grade 3, 33.3%) Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701
2.4 mg/m2 3 times / week multiple, intravenous MTD Dose: 2.4 mg/m2, 3 times / week Route: intravenous Route: multiple Dose: 2.4 mg/m2, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.704	unhealthy, 32-83 n = 6 Health Status: unhealthy Condition: Cancer Age Group: 32-83 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.704	Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.704
2.25 mg/m2 1 times / week multiple, intravenous Recommended Dose: 2.25 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2.25 mg/m2, 1 times / week Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202497s011lbl.pdf Page: p.8	unhealthy n = 83 Health Status: unhealthy Condition: Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) Population Size: 83 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202497s011lbl.pdf Page: p.8	Disc. AE: Peripheral neuropathy, Tumor lysis syndrome... AEs leading to discontinuation/dose reduction: Peripheral neuropathy (10%) Tumor lysis syndrome (2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202497s011lbl.pdf Page: p.8

AEs

AE	Significance	Dose	Population
Motor polyneuropathy	grade 3, 14.3% DLT	2.4 mg/m2 1 times / week multiple, intravenous Studied dose Dose: 2.4 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2.4 mg/m2, 1 times / week Co-administed with:: dexamethasone, i.v.(40 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6	unhealthy, 19-62 n = 7 Health Status: unhealthy Condition: Acute lymphoblastic leukemia Age Group: 19-62 Sex: M+F Population Size: 7 Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6
Hepatotoxicity	grade 4, 14.3% DLT	2.4 mg/m2 1 times / week multiple, intravenous Studied dose Dose: 2.4 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2.4 mg/m2, 1 times / week Co-administed with:: dexamethasone, i.v.(40 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6	unhealthy, 19-62 n = 7 Health Status: unhealthy Condition: Acute lymphoblastic leukemia Age Group: 19-62 Sex: M+F Population Size: 7 Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6
Seizure	grade 4, 14.3% DLT	2.4 mg/m2 1 times / week multiple, intravenous Studied dose Dose: 2.4 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2.4 mg/m2, 1 times / week Co-administed with:: dexamethasone, i.v.(40 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6	unhealthy, 19-62 n = 7 Health Status: unhealthy Condition: Acute lymphoblastic leukemia Age Group: 19-62 Sex: M+F Population Size: 7 Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6
Obstipation	DLT	2.8 mg/m2 3 times / week multiple, intravenous Highest studied dose Dose: 2.8 mg/m2, 3 times / week Route: intravenous Route: multiple Dose: 2.8 mg/m2, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701	unhealthy, 32-83 n = 3 Health Status: unhealthy Condition: Cancer Age Group: 32-83 Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701
Myalgia	grade 3, 33.3% DLT	2.8 mg/m2 3 times / week multiple, intravenous Highest studied dose Dose: 2.8 mg/m2, 3 times / week Route: intravenous Route: multiple Dose: 2.8 mg/m2, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701	unhealthy, 32-83 n = 3 Health Status: unhealthy Condition: Cancer Age Group: 32-83 Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701
Neutropenia	grade 4, 33.3% DLT	2.8 mg/m2 3 times / week multiple, intravenous Highest studied dose Dose: 2.8 mg/m2, 3 times / week Route: intravenous Route: multiple Dose: 2.8 mg/m2, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701	unhealthy, 32-83 n = 3 Health Status: unhealthy Condition: Cancer Age Group: 32-83 Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701
Thrombocytopenia	grade 4, 33.3% DLT	2.8 mg/m2 3 times / week multiple, intravenous Highest studied dose Dose: 2.8 mg/m2, 3 times / week Route: intravenous Route: multiple Dose: 2.8 mg/m2, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701	unhealthy, 32-83 n = 3 Health Status: unhealthy Condition: Cancer Age Group: 32-83 Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701
Peripheral neuropathy	10% Disc. AE	2.25 mg/m2 1 times / week multiple, intravenous Recommended Dose: 2.25 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2.25 mg/m2, 1 times / week Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202497s011lbl.pdf Page: p.8	unhealthy n = 83 Health Status: unhealthy Condition: Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) Population Size: 83 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202497s011lbl.pdf Page: p.8
Tumor lysis syndrome	2% Disc. AE	2.25 mg/m2 1 times / week multiple, intravenous Recommended Dose: 2.25 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2.25 mg/m2, 1 times / week Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202497s011lbl.pdf Page: p.8	unhealthy n = 83 Health Status: unhealthy Condition: Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) Population Size: 83 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202497s011lbl.pdf Page: p.8

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1670		substrate 1168	inhibitor 1570

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP2C19 955 P-gp 1491

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP2C19 955	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202497Orig1s000ClinPharmR.pdf#page=31 Page: 31.0	likely
CYP2D6 1168	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202497Orig1s000ClinPharmR.pdf#page=31 Page: 31.0	likely
P-gp 1491	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/17029589/	yes
CYP3A4 1670	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202497Orig1s000ClinPharmR.pdf#page=31; https://pubmed.ncbi.nlm.nih.gov/10613614/ Page: 31.0	yes	yes (co-administration study) Comment: the total area under the plasma concentration-time curve was 43% smaller in patients who were receiving carbamazepine or phenytoin than in the control group; the concomitant use of strong CYP3A inhibitors should be avoided (e.g., ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin). Similarly, the concomitant use of strong CYP3A inducers should be avoided (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, St. John’s Wort) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202497Orig1s000ClinPharmR.pdf#page=31; https://pubmed.ncbi.nlm.nih.gov/10613614/ Page: 31.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1603	inhibitor 1584 Sources: https://pubmed.ncbi.nlm.nih.gov/15812674/ Page: 4.0

Sourcing

Vendor/Aggregator	ID	URL
AK Scientific	E375
AbovChem LLC	HY-N0488
BOC Sciences	2068-78-2
BioSynth	Q-201925
Biopurify Phytochemicals	BP1439
Biopurify Phytochemicals	BP1440
Bosche Scientific	V1207
Cayman Chemical	11764
Chem Scene	CS-1778
Hangzhou APIChem Technology	AC-22619
Hangzhou Yuhao Chemical Technology	RT14234
IBScreen	STOCK1N-40733
KeyOrganics	AS-12168
MedChem Express	HY-N0488
MolPort	MolPort-002-519-272
MolPort	MolPort-003-939-860
MolPort	MolPort-035-789-673
Sigma Aldrich	1714007
Sigma Aldrich	V0400000
Sigma Aldrich	V0400000\|SIAL
Sigma Aldrich	V8388\|SIAL
Sigma Aldrich	V8879\|SIGMA
ZINC	ZINC000085537024	http://zinc15.docking.org/substances/ZINC000085537024
eMolecules	32176538
eMolecules	50241482
eMolecules	95704370
mcule	MCULE-1562099693
mcule	MCULE-3827132352

PubMed

Title	Date	PubMed
Vincristine-induced autonomic neuropathy.	1975 Jul 26	1148735
Fatal myeloencephalopathy due to intrathecal vincristine administration.	1992	1280054
Combined intra-arterial and systemic chemotherapy for recurrent malignant brain tumors.	1992 Feb	1312230
Vincristine neurotoxicity.	1992 Mar	1319399
[Establishment of MRP-overexpression subline of bladder carcinoma and its MDR phenotype].	2000 Jul	11778547
Venoocclusive liver disease (VOD) as a complication of Wilms' tumour management in the series of consecutive 206 patients.	2000 Oct	11194540
Cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) for advanced-stage Hodgkin's disease: CALGB 8856.	2001	11458812
Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease.	2001 Apr	11328296
Discovery of a novel compound: insight into mechanisms for acrylamide-induced axonopathy and colchicine-induced apoptotic neuronal cell death.	2001 Aug 3	11478917
Adult medulloblastoma: multiagent chemotherapy.	2001 Jan	11305414
Treatment of classical type Kaposi's sarcoma with paclitaxel.	2001 Jan-Feb	11299806
Experience with vincristine--associated neurotoxicity.	2001 Jul	11957264
Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis.	2001 Jul	11438417
Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia.	2001 Mar	11255732
Motor nervous pathway function is impaired after treatment of childhood acute lymphoblastic leukemia: a study with motor evoked potentials.	2001 Mar	11241435
Mutation of a single conserved tryptophan in multidrug resistance protein 1 (MRP1/ABCC1) results in loss of drug resistance and selective loss of organic anion transport.	2001 May 11	11278867
ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial.	2001 May 18	11355937
Delayed functional recovery by vincristine after sciatic nerve crush injury: a mouse model of vincristine neurotoxicity.	2001 May 18	11335041
Ischemic heart disease associated with vincristine and doxorubicin chemotherapy.	2001 Nov	11724093
Fatal myeloencephalopathy due to accidental intrathecal vincristin administration: a report of two cases.	2001 Oct 15	11587867
Inhibition of drug-induced Fas ligand transcription and apoptosis by Bcl-XL.	2001 Sep	11716366
Hyponatremia and syndrome of inappropriate anti-diuretic hormone reported with the use of Vincristine: an over-representation of Asians?	2002 Apr-May	12051122
Epidemiology of Burkitt's lymphoma in Enugu, Nigeria.	2002 Dec	12530287
Identification and characterization of the canine multidrug resistance-associated protein.	2002 Dec	12516967
Posttransplantation lymphoproliferative disorder presenting as a unilateral leg mass 10 years after kidney transplantation.	2002 Dec 15	12490805
Vincristine-induced vocal cord paralysis in an infant.	2002 Feb	11882230
A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy.	2002 Jun	12225393
Functional analysis of MRP1 cloned from bovine.	2002 Jun 19	12067707
A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.	2002 May 1	12015757
Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma.	2002 Nov-Dec	12465768
Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma.	2002 Oct	12358915
A novel case of a CAT to AAT transversion in codon 179 of the p53 gene in a supratentorial primitive neuroectodermal tumor harbored by a young girl. Case report and review of the literature.	2003	12837982
Sexual dimorphism for protein kinase c epsilon signaling in a rat model of vincristine-induced painful peripheral neuropathy.	2003	12809704
Altered temporal pattern of evoked afferent activity in a rat model of vincristine-induced painful peripheral neuropathy.	2003	12710988
[Clinical analysis of 75 patients with nasopharyngeal non-Hodgkin's lymphoma].	2003 Apr	12703998
Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study.	2003 Apr	12679647
[Anaphylaxia induced by etoposide--a case report].	2003 Aug	12938279
Henoch-Schönlein IgA glomerulonephritis complicating myeloma kidneys: case report.	2003 Aug	12844235
The effects of chemotherapeutic agents on the regulation of thrombin on cell surfaces.	2003 Jan	12542493
Vincristine neurotoxicity in the presence of hereditary neuropathy.	2003 Jan	12426685
NOVP chemotherapy for Hodgkin's disease transiently induces sperm aneuploidies associated with the major clinical aneuploidy syndromes involving chromosomes X, Y, 18, and 21.	2003 Jan 1	12517776
Toxic neuropathy in patients with pre-existing neuropathy.	2003 Jan 28	12552058
Spinal sensitization mechanism in vincristine-induced hyperalgesia in mice.	2003 Jun 5	12759171
Cloning and functional characterization of the multidrug resistance-associated protein (MRP1/ABCC1) from the cynomolgus monkey.	2003 Mar	12657726
Changes in sensory processing in the spinal dorsal horn accompany vincristine-induced hyperalgesia and allodynia.	2003 May	12749967
Leiomyosarcoma of urinary bladder following cyclophosphamide therapy: report of two cases.	2003 May	12748258
Functional and structural consequences of cysteine substitutions in the NH2 proximal region of the human multidrug resistance protein 1 (MRP1/ABCC1).	2003 May 13	12731862
The egr-1 gene is induced by DNA-damaging agents and non-genotoxic drugs in both normal and neoplastic human cells.	2003 May 16	12706485
Charcot-Marie-Tooth disease and vincristine.	2003 May-Jun	12756314
Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma.	2003 Oct 1	12791655

Patents

Sample Use Guides

In Vivo Use Guide

Marqibo is liposome-encapsulated vincristine. 2.25 mg/m2 intravenously over 1 hour once every 7 days.

Route of Administration: Intravenous

In Vitro Use Guide

Treatment of macrophage monolayers for 24 h with vincristine (10(-5)-10(-7) M) inhibited the antibody dependent cellular cytotoxicity (ADCC) by PMA stimulated rat macrophages.

Substance Class	Chemical Created by `admin` on `Fri Dec 16 15:53:29 UTC 2022` Edited by `admin` on `Fri Dec 16 15:53:29 UTC 2022`
Record UNII	T5IRO3534A
Record Status	`Validated (UNII)`
Record Version

Download

Related Record	Type

Name

Type

Language

VINCRISTINE SULFATE

Official Name

English

VINCRISTINE SULFATE [IARC]

Common Name

English

VINCRISTINI SULFAS [WHO-IP LATIN]

Common Name

English

VINCRISUL

Common Name

English

22-OXOVINCALEUKOBLASTINE SULFATE (1:1) (SALT) [WHO-IP]

Common Name

English

VINCRISTINE SULFATE [MART.]

Common Name

English

37231

Code

English

Leurocristine sulfate (1:1) (salt)

Common Name

English

NSC-67574

Code

English

VINCRISTINE SULFATE [JAN]

Common Name

English

Vincristine sulfate [WHO-DD]

Common Name

English

VINCRISTINE SULFATE [USAN]

Common Name

English

VINCRISTINE SULFATE [EP MONOGRAPH]

Common Name

English

VINCRISTINE SULFATE [USP-RS]

Common Name

English

KYOCRISTINE

Common Name

English

VINCALEUKOBLASTINE, 22-OXO-, SULFATE (1:1) (SALT)

Common Name

English

VINCRISTINE SULFATE [VANDF]

Common Name

English

ONCOVIN

Brand Name

English

VINCRISTINE SULFATE [WHO-IP]

Common Name

English

VINCREX

Brand Name

English

VINCRISTINE SULFATE [MI]

Common Name

English

VINCRISTINE SULPHATE

Common Name

English

NOVOPHARM

Common Name

English

LILLY-37231

Code

English

VINCRISTINE SULFATE [USP MONOGRAPH]

Common Name

English

VINCRISTINE SULFATE [ORANGE BOOK]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

259108